Pacific Bio (PACB) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pacific Biosciences of California, Inc. Announces Second Quarter 2017 Financial Results
August 2, 2017 4:02 PM EDTMENLO PARK, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2017.
Product, service and other revenue for the second quarter of 2017 increased by 17% to $20.1 million, compared to $17.2 million for the second quarter of 2016. Total revenue for the second quarter of 2017 was $20.1 million, compared to $20.7 million for the second quarter of 2016. Total revenue for the second quarter of 2016 included $3.6 million of contractual revenue, whereas the second quarter of 2017 included no contractual revenue.Â
Gross profit for the second quarter of... More
